top of page

For the few who shape what's next.

The gap

Most organisations have already invested in AI infrastructure. The technology is not the bottleneck. Leadership confidence is.

​

When decisions are material, executives hesitate to let AI influence outcomes. Pilots stall. Validation cycles repeat. "We need more data" becomes a proxy for "we don't yet know how to govern this."

The room

​

AIO Circle is an invite-only governance and strategy platform for up to 50 senior leaders responsible for AI-shaped decisions across drug discovery, development and biomanufacturing.

​

It exists to close the gap between infrastructure investment and institutional confidence - helping executives move from pilots to governed, auditable systems in production.

​

The focus is accountability, operating architecture and the frameworks that make AI-enabled decisions explainable, defensible and scalable in regulated life science environments.

​

Built for

Decision-makers who sign their name under the outcome.

​

CEOs, CTOs, CSOs, COOs, AIOs, Heads of Manufacturing, MSAT and CMC leaders, Quality and Regulatory executives, R&D and Drug Discovery leaders, Digital and AI officers — across biologics, cell and gene therapy and alternative proteins.

The AIO

Feature

90 minutes.

Cross-brand. One question:

What does it mean to lead AI across discovery, development, biomanufacturing and food-tech?

​

How are AI, data architecture and process intelligence reshaping how drug discovery, CGTs, biotherapeutics and alternative proteins are discovered, scaled and delivered – and what does that demand of the leaders in charge?

26Action_GBXcircle_Leadershippng_edited.jpg

The lens:

* How AI and data infrastructure become shared "nervous systems" across biotechs, CDMOs, pharma and platform companies.

​

* How an AIO designs and governs systems that move therapies and proteins faster, more reliably and with clearer evidence.

17Action_GBXcircle_Leadershippng.png

The format:

* Day 1: Big picture.

How AI leadership redefines value creation.

​

* Day 2: Concrete remit.

AI, data, automation and process intelligence as enterprise utilities—not projects.

​

* Close: Leaders' panel.

Responsibilities, metrics, operating models.

probert_edited_edited_edited_edited_edited.png
GBX Circle Staff_edited.png

Strategic Priorities for Leadership.

1 / AIO 90 mins features - @ BILS. MEVO | DDIF. SCIS.

  • AI governance in life sciences

  • Automation in drug discovery and biomanufacturing

  • Regulatory compliance for AI-enabled systems

  • Operational technology in pharma manufacturing

  • Data integrity and auditability

  • Digital transformation in biologics and CGT

  • Leadership decision-making in regulated environments

  • Manufacturing excellence and process automation

  • Lab automation and smart manufacturing

  • Cross-functional alignment in biopharma operations

2 / Workforce Leadership Panels.

  • Talent shortage as growth barrier

  • Biopharma 4.0 skillset requirements

  • Training one team across modalities

  • GMP workforce development

  • Digital manufacturing talent gap

  • Automation and workforce redesign

  • 1/3 workforce, 3x productivity thesis

  • Human-machine collaboration

  • Academic-industry training partnerships

  • Upskilling and reskilling programmes

  • Leadership for operational transformation

3 / Supper club themes. Showcases. Members only.

  • AI moving from hype to accountability

  • Execution over potential

  • Disciplined re-acceleration

  • Creating distance not optimising

  • The bottleneck is people

  • Convergence as competitive advantage

  • Show your work

  • Health-economic discipline

  • Biomanufacturing reshoring as strategic priority

  • Talent precedes infrastructure

bottom of page